For­mer Voy­ager CEO An­dre Turenne makes a come­back with At­las-backed co­va­lent drug biotech 

Last May, An­dre Turenne re­signed from his CEO and pres­i­dent posts at Voy­ager to “pur­sue oth­er op­por­tu­ni­ties” af­ter the neu­ro­science biotech, once one half of ma­jor part­ner­ships with Sanofi, Ab­b­Vie and Neu­ro­crine, faced one set­back af­ter an­oth­er that put it and its gene ther­a­pies out of the clin­ic — though it’s now stag­ing a come­back with for­mer Bio­gen R&D chief Al San­drock at the helm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER